A study of rivastigmine liposomes for delivery into the brain through intranasal route

Karthik Arumugam, Ganesa Sundararajan Subramanian, Rajan M Surulivel, Ranjith Kumar Averineni, Meka Sreenivasa Reddy, Nayanabhirama Udupa

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

The present study is mainly aimed at delivering a drug into the brain via the intranasal route using a liposomal formulation. For this purpose, rivastigmine, which is used in the management of Alzheimer's disease, was selected as a model drug. Conventional liposomes were formulated by the lipid layer hydration method using cholesterol and soya lecithin as lipid components. The concentration of rivastigmine in brain and plasma after intranasal liposomes, free drug and per oral administration was studied in rat models. A significantly higher level of drug was found in the brain with intranasal liposomes of rivastigmine compared to the intranasal free drug and the oral route. Intranasal liposomes had a longer half-life in the brain than intranasally or orally administered free drug. Delivering rivastigmine liposomes through the intranasal route for the treatment of Alzheimer's disease might be a new approach to the management of this condition.

Original languageEnglish
Pages (from-to)287-297
Number of pages11
JournalActa Pharmaceutica
Volume58
Issue number3
DOIs
Publication statusPublished - 09-2008

Fingerprint

Rivastigmine
Liposomes
Brain
Pharmaceutical Preparations
Alzheimer Disease
Lipids
Lecithins
Oral Administration
Half-Life
Cholesterol

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Pharmacology
  • Pharmaceutical Science

Cite this

Arumugam, Karthik ; Subramanian, Ganesa Sundararajan ; Surulivel, Rajan M ; Averineni, Ranjith Kumar ; Reddy, Meka Sreenivasa ; Udupa, Nayanabhirama. / A study of rivastigmine liposomes for delivery into the brain through intranasal route. In: Acta Pharmaceutica. 2008 ; Vol. 58, No. 3. pp. 287-297.
@article{c146d4e489ad47219d90b99ba04c6438,
title = "A study of rivastigmine liposomes for delivery into the brain through intranasal route",
abstract = "The present study is mainly aimed at delivering a drug into the brain via the intranasal route using a liposomal formulation. For this purpose, rivastigmine, which is used in the management of Alzheimer's disease, was selected as a model drug. Conventional liposomes were formulated by the lipid layer hydration method using cholesterol and soya lecithin as lipid components. The concentration of rivastigmine in brain and plasma after intranasal liposomes, free drug and per oral administration was studied in rat models. A significantly higher level of drug was found in the brain with intranasal liposomes of rivastigmine compared to the intranasal free drug and the oral route. Intranasal liposomes had a longer half-life in the brain than intranasally or orally administered free drug. Delivering rivastigmine liposomes through the intranasal route for the treatment of Alzheimer's disease might be a new approach to the management of this condition.",
author = "Karthik Arumugam and Subramanian, {Ganesa Sundararajan} and Surulivel, {Rajan M} and Averineni, {Ranjith Kumar} and Reddy, {Meka Sreenivasa} and Nayanabhirama Udupa",
year = "2008",
month = "9",
doi = "10.2478/v10007-008-0014-3",
language = "English",
volume = "58",
pages = "287--297",
journal = "Acta Pharmaceutica",
issn = "1330-0075",
publisher = "Croatian Pharmaceutical Society",
number = "3",

}

A study of rivastigmine liposomes for delivery into the brain through intranasal route. / Arumugam, Karthik; Subramanian, Ganesa Sundararajan; Surulivel, Rajan M; Averineni, Ranjith Kumar; Reddy, Meka Sreenivasa; Udupa, Nayanabhirama.

In: Acta Pharmaceutica, Vol. 58, No. 3, 09.2008, p. 287-297.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A study of rivastigmine liposomes for delivery into the brain through intranasal route

AU - Arumugam, Karthik

AU - Subramanian, Ganesa Sundararajan

AU - Surulivel, Rajan M

AU - Averineni, Ranjith Kumar

AU - Reddy, Meka Sreenivasa

AU - Udupa, Nayanabhirama

PY - 2008/9

Y1 - 2008/9

N2 - The present study is mainly aimed at delivering a drug into the brain via the intranasal route using a liposomal formulation. For this purpose, rivastigmine, which is used in the management of Alzheimer's disease, was selected as a model drug. Conventional liposomes were formulated by the lipid layer hydration method using cholesterol and soya lecithin as lipid components. The concentration of rivastigmine in brain and plasma after intranasal liposomes, free drug and per oral administration was studied in rat models. A significantly higher level of drug was found in the brain with intranasal liposomes of rivastigmine compared to the intranasal free drug and the oral route. Intranasal liposomes had a longer half-life in the brain than intranasally or orally administered free drug. Delivering rivastigmine liposomes through the intranasal route for the treatment of Alzheimer's disease might be a new approach to the management of this condition.

AB - The present study is mainly aimed at delivering a drug into the brain via the intranasal route using a liposomal formulation. For this purpose, rivastigmine, which is used in the management of Alzheimer's disease, was selected as a model drug. Conventional liposomes were formulated by the lipid layer hydration method using cholesterol and soya lecithin as lipid components. The concentration of rivastigmine in brain and plasma after intranasal liposomes, free drug and per oral administration was studied in rat models. A significantly higher level of drug was found in the brain with intranasal liposomes of rivastigmine compared to the intranasal free drug and the oral route. Intranasal liposomes had a longer half-life in the brain than intranasally or orally administered free drug. Delivering rivastigmine liposomes through the intranasal route for the treatment of Alzheimer's disease might be a new approach to the management of this condition.

UR - http://www.scopus.com/inward/record.url?scp=53549135761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53549135761&partnerID=8YFLogxK

U2 - 10.2478/v10007-008-0014-3

DO - 10.2478/v10007-008-0014-3

M3 - Article

C2 - 19103565

AN - SCOPUS:53549135761

VL - 58

SP - 287

EP - 297

JO - Acta Pharmaceutica

JF - Acta Pharmaceutica

SN - 1330-0075

IS - 3

ER -